- Works count
- 1,505
- Citation count
- 71,209
- H-index
- 129
- i10-index
- 724
Research interests
Publications
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
The Lancet · 2025 · https://doi.org/10.1016/s0140-6736(25)01042-6
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00242-5
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
HepatoBiliary Surgery and Nutrition · 2022 · https://doi.org/10.21037/hbsn-21-328
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00252-7
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Cell · 2020 · https://doi.org/10.1016/j.cell.2020.11.041
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Liver Cancer · 2020 · https://doi.org/10.1159/000509424
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Cell · 2019 · https://doi.org/10.1016/j.cell.2019.08.052
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Nature · 2019 · https://doi.org/10.1038/s41586-019-0987-8
Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer
Nature · 2018 · https://doi.org/10.1038/s41586-018-0350-5
Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma
Gastroenterology · 2017 · https://doi.org/10.1053/j.gastro.2017.09.025
STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4
Molecular Cancer · 2017 · https://doi.org/10.1186/s12943-017-0680-1
Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Clinical Cancer Research · 2014 · https://doi.org/10.1158/1078-0432.ccr-14-0442
Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma
Cancer Cell · 2013 · https://doi.org/10.1016/j.ccr.2013.11.011
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus–related hepatocellular carcinoma
Nature Genetics · 2012 · https://doi.org/10.1038/ng.2483
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study
The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70233-4
Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma
Molecular & Cellular Proteomics · 2011 · https://doi.org/10.1074/mcp.m110.004945
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride
Journal of Hepatology · 2010 · https://doi.org/10.1016/j.jhep.2010.05.018
MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0901282
Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection
Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.09.4565
Current projects
No projects listed.